Rosen Law Firm has filed class action lawsuits against Oracle Corporation, Corcept Therapeutics, and Endeavor Group Holdings on behalf of investors who purchased common stock during specified periods. The Oracle lawsuit alleges the company made false statements regarding its AI infrastructure strategy, resulting in massive CapEx increases without equivalent revenue growth and creating risks to debt, credit rating, and cash flow. Lead plaintiff deadlines vary by case, with investors encouraged to secure counsel.

Rosen Law Firm has filed a class action lawsuit against Corcept Therapeutics on behalf of investors who purchased common stock between October 31, 2024 and December 30, 2025. The lawsuit alleges that Corcept made misleading statements about its relacorilant drug's clinical trial data and FDA approval prospects, while the FDA had raised concerns about the adequacy of clinical evidence supporting the New Drug Application.

A securities class action lawsuit has been filed against Corcept Therapeutics for allegedly misleading investors about its lead drug candidate relacorilant. The company claimed the drug had 'powerful evidence' and was 'approaching approval,' but the FDA had privately warned of inadequate clinical data. On December 31, 2025, Corcept received a Complete Response Letter from the FDA, causing the stock to plunge 50% from $70.20 to $34.80, erasing $3.6 billion in market value. Investors have until April 21, 2026, to file as lead plaintiffs.

A class action lawsuit has been filed against Corcept Therapeutics Incorporated for alleged securities fraud. The complaint alleges that defendants made materially false and misleading statements about the strength of clinical trials supporting relacorilant and overstated confidence in its regulatory approval prospects, while failing to disclose known risks that the FDA would reject the NDA application.

A class action lawsuit has been filed against Corcept Therapeutics on behalf of investors who purchased securities between October 31, 2024 and December 31, 2025. The lawsuit alleges that Corcept misrepresented the strength of clinical evidence supporting its relacorilant drug candidate and concealed known FDA concerns about the application. On December 31, 2025, Corcept disclosed that the FDA issued a Complete Response Letter rejecting the relacorilant NDA, causing the stock to fall over 50%. The FDA's redacted letter revealed it had repeatedly warned Corcept about inadequate clinical evidence during pre-submission meetings.

Corcept Therapeutics is facing a securities class action lawsuit for allegedly failing to disclose material information about its lead drug candidate relacorilant. The FDA issued a Complete Response Letter on December 31, 2025, rejecting the drug application, causing Corcept's stock to plummet 50.4% in a single day. Investors with losses exceeding $100,000 have until April 21, 2026 to file lead plaintiff applications.

A securities class action lawsuit has been filed against Corcept Therapeutics alleging the company misled investors about its lead drug relacorilant's regulatory viability. The lawsuit claims Corcept ignored repeated FDA warnings about inadequate clinical data while publicly expressing confidence in approval. The stock plunged 50% (from $70.20 to $34.80) on December 31, 2025, when the FDA issued a Complete Response Letter rejecting the drug application, erasing $3.6 billion in market value. Investors have until April 21, 2026, to file as lead plaintiffs.

Kahn Swick & Foti, LLC has filed securities fraud class action lawsuits against uniQure N.V., Corcept Therapeutics, and BellRing Brands for allegedly failing to disclose material information to investors. uniQure's stock declined 49% after the FDA rejected data supporting its drug candidate AMT-130's accelerated approval. Similar FDA approval issues and inventory problems caused significant stock declines at the other companies. Investors have until April 13, 2026 to file lead plaintiff applications.

Kahn Swick & Foti, LLC announced multiple securities fraud class action lawsuits against pharmaceutical and consumer companies. Corcept Therapeutics faces allegations of failing to disclose material information about its relacorilant drug candidate, which received a Complete Response Letter from the FDA instead of approval, causing a 50.4% stock decline. Similar lawsuits were filed against uniQure N.V. for FDA approval delays (49% decline) and BellRing Brands for inventory issues (52% decline). Investors have until April 21, 2026 to file lead plaintiff applications.

Kahn Swick & Foti, LLC has filed securities fraud class action lawsuits against BellRing Brands, uniQure N.V., and Corcept Therapeutics for allegedly failing to disclose material information. BellRing's stock declined 52% following inventory and retailer supply issues, uniQure's stock fell 49% due to FDA approval delays, and Corcept's stock dropped 50% related to FDA approval issues. Investors have until March 23, 2026 to file lead plaintiff applications.

A class action lawsuit has been filed against Corcept Therapeutics for allegedly misrepresenting the strength of clinical evidence supporting its relacorilant drug for Cushing's syndrome treatment. The company claimed the drug was 'approaching approval' despite FDA concerns about inadequate clinical evidence. On December 31, 2025, the FDA issued a Complete Response Letter rejecting the application, causing Corcept's stock to plummet 50.4% from $70.20 to $34.80.

Bernstein Liebhard LLP announces shareholder class action lawsuits against three companies: Corcept Therapeutics for misrepresentations regarding clinical evidence for relacorilant; Zynex for unspecified shareholder claims; and NuScale Power for shareholder disputes. Investors who purchased shares during specified periods are eligible to participate in the litigation.